CTP (Euronext Amsterdam:CTPNV), an owner, developer and manager of logistics and industrial real estate, has completed an 18,000 square metre build-to-suit production facility for SCHOTT Pharma (ETR:1SXP) at CTPark Jagodina in Serbia, the company announced on Monday.

The facility will support SCHOTT Pharma's production of high-quality glass ampoules for vaccines and other medications.

This development marks an expansion of SCHOTT Pharma's global manufacturing network, which now spans 15 countries. The Jagodina facility complements 10 existing ampoule manufacturing sites and will employ 180 people to help deliver billions of injections annually.

Located near Serbia's A1 highway, CTPark Jagodina offers direct road access to key cities including Belgrade and Niš, as well as multiple European Union markets. The site also benefits from a strong local talent pool, with 400,000 residents within 50 km and 20,000 students nearby.

The facility meets CTP's high sustainability standards, including BREEAM Very Good certification, rooftop solar systems and water reuse infrastructure. CTPark Jagodina spans 22.9 hectares, with 33,000 square metres built and 88,000 square metres planned.

CTP currently manages 600,000 square metres of gross leasable area in Serbia, with an additional 200,000 square metres scheduled for delivery in 2025. Serbia's strategic location and labour availability make it increasingly attractive for multinationals nearshoring production to Europe.